PedMAb1 trial: safety of two broadly neutralising antibodies, CAP256V2LS and VRC07-523LS, administered singly or concurrently at birth and 3 months to breastfeeding HIV-1 exposed neonates and infants born without HIV

Conference Reports for NATAP

IAS 2025, 13th IAS Conference on HIV Science
Kigali, Rwanda
July 13-17


PedMAb1 trial: safety of two broadly neutralising antibodies, CAP256V2LS and VRC07-523LS, administered singly or concurrently at birth and 3 months to breastfeeding HIV-1 exposed neonates and infants born without HIV

	IAS 2025 July 13-17 Rwanda ( G. SCARLATTI )